HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XNCR
Xencor, Inc.
XNCR lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XNCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Strong |
XNCR's revenue and balance sheet are currently strong, but its profitability and cash flow are weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XNCR PE Valuation
XNCR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XNCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect XNCR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
XNCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.59 | +$0.13 |
| Q2 2026 | -$2.17 | +$0.19 |
| Q1 2026 | -$2.29 | +$0.75 |
| Q4 2025 | -$1.24 | +$2.34 |
| Q3 2025 | -$1.72 | +$1.70 |
| Q2 2025 | -$2.36 | +$0.74 |
| Q1 2025 | -$3.04 | -$0.66 |
| Q4 2024 | -$3.58 | -$1.38 |
XNCR has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XNCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
XNCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $116.5M | +455% |
| Q2 2026 | $51.2M | +17% |
| Q1 2026 | $4.5M | -86% |
| Q4 2025 | $28.2M | -47% |
| Q3 2025 | $21M | +18% |
| Q2 2025 | $43.6M | +82% |
| Q1 2025 | $32.7M | +105% |
| Q4 2024 | $52.8M | +3.6% |
XNCR's revenue is recovering but still below its 2021 peak: $117M last quarter, up 455% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +246 points |
| Q2 2026 | -72% | +3.7 points |
| Q1 2026 | -1724% | -1592 points |
| Q4 2025 | -190% | -165 points |
| Q3 2025 | -226% | +84 points |
| Q2 2025 | -76% | +156 points |
| Q1 2025 | -132% | +210 points |
| Q4 2024 | -25% | +29 points |
XNCR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over XNCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XNCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $838K | +$31.8M |
| Q2 2026 | -$56.2M | -$19.4M |
| Q1 2026 | -$68.2M | -$50.6M |
| Q4 2025 | -$52.9M | -$1.4M |
| Q3 2025 | -$31M | -$1.6M |
| Q2 2025 | -$36.8M | +$33.6M |
| Q1 2025 | -$17.7M | +$39.3M |
| Q4 2024 | -$51.5M | -400% |
XNCR has burned cash in most quarters: −$176M over the past year, against −$137M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XNCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XNCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +2.5M shares |
| 1 year | +5.3% | +3.9M shares |
| 3 years | +29% | +17.7M shares |
| 5 years | +34% | +20M shares |
| Available history | +34% | +19.9M shares |
XNCR has 78M diluted shares, up 5.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XNCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -0.9x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -0.8x | Net Cash |
| Q4 2021 | -2.8x | Net Cash |
| Q4 2019 | -2.8x | Net Cash |
XNCR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XNCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 81.4 | Overbought |
| Stochastic | 85.8 | Overbought |
XNCR's weekly RSI is 81 (overbought) and its Stochastic is 86 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XNCR PE vs Healthcare Sector
| Metric | XNCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XNCR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XNCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.1 | 36% above |
| 20 week MA | $24.3 | 57% above |
| 50 week MA | $17.5 | 118% above |
| 100 week MA | $15.0 | 154% above |
| 200 week MA | $19.0 | 101% above |
XNCR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
XNCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $46.1 | +30% |
| 2021 | $46.1 | $40.7 | -12% |
| 2022 | $40.7 | $26.1 | -36% |
| 2023 | $26.1 | $21.2 | -19% |
| 2024 | $21.2 | $24.3 | +14% |
| 2025 | $24.3 | $15.2 | -37% |
| 2026 YTD | $15.2 | $38.1 | +151% |
XNCR has the edge over HIMS on returns for 2026, with the stronger performance.